HIỆU QUẢ CỦA PHÁC ĐỒ SOFOSBUVIR/DACLATASVIR Ở BỆNH NHÂN VIÊM GAN VI RÚT C CÓ XƠ GAN TẠI BỆNH VIỆN BỆNH NHIỆT ĐỚI TRUNG ƯƠNG

Abstract

Objectives: This study was carried out to evaluate the results of Sofosbuvir plus Daclatasvir in chronic hepatitis C (CHC) patients with cirrhosis.

Subjects and methods: Between July 2017 and January 2019, a total of 30 CHC patients with cirrhosis were enrolled in the study. All of them completed 24 weeks combination of SOF (400mg/day) plus DCV (60 mg/day) and were followed up at weeks 4, 12, 24 (end - of - treatment).

Results: The mean age was 59.0 ± 14 years, 21 (70%) of them were males. Severity of liver diseases was as follows: 30% F3 and 70% F4, Child - Pugh A cirrhosis 93.33%; and Child - Pugh B cirrhosis 6.67%. At weeks 4 and 24, the rate of normalization of enzyme ALT and AST was 66.67% and 73.33%, respectively. There were 90% of patients with undetectable HCV RNA (< 15IU/mL) at weeks 4. At the end - of - treatment, HCV - RNA was undetectable in 100% of patients. The level of fibrosis and cirrhosis was reduced significantly at weeks 24 when compaired to week 0 (12.6 kpa versus 16.95 kPa, p < 0.05). The level of fibrosis was improved in 33.33% of patients. Of them, 6 patients reduced from F4 to F0 - 1, F2, F3.

Conclusion: Sofosbuvir and Daclatasvir was highly effective for treatment of chronic hepatitis C patients with cirrhosis.